CA3181788A1 - Test viral dans la salive - Google Patents

Test viral dans la salive

Info

Publication number
CA3181788A1
CA3181788A1 CA3181788A CA3181788A CA3181788A1 CA 3181788 A1 CA3181788 A1 CA 3181788A1 CA 3181788 A CA3181788 A CA 3181788A CA 3181788 A CA3181788 A CA 3181788A CA 3181788 A1 CA3181788 A1 CA 3181788A1
Authority
CA
Canada
Prior art keywords
virus
saliva
nucleic acid
viral
viral nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3181788A
Other languages
English (en)
Inventor
Shi-long LU
Brian L. Harry
Jose P. Zevallos
Robert E. Blomquist
Xin Yao
Yue Qiu
Marsha T. Tharakan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lu Shi Long
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3181788A1 publication Critical patent/CA3181788A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un test à base de salive pour des virus tels que le SARS-CoV-2. Des procédés de collecte simples permettent une collecte à domicile, réduisant le risque et la charge imposés aux professionnels de la santé lors de l'utilisation des procédés de test classiques. Les tests permettent d'analyser quantitativement à la fois les acides nucléiques viraux pour évaluer la charge virale ainsi que des anticorps spécifiques du virus pour suivre la progression de la maladie et l'immunité potentielle.
CA3181788A 2020-04-29 2021-04-29 Test viral dans la salive Pending CA3181788A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017354P 2020-04-29 2020-04-29
US63/017,354 2020-04-29
PCT/US2021/029897 WO2021222569A1 (fr) 2020-04-29 2021-04-29 Test viral dans la salive

Publications (1)

Publication Number Publication Date
CA3181788A1 true CA3181788A1 (fr) 2021-11-04

Family

ID=78292204

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3181788A Pending CA3181788A1 (fr) 2020-04-29 2021-04-29 Test viral dans la salive

Country Status (5)

Country Link
US (1) US20210341480A1 (fr)
EP (1) EP4143348A4 (fr)
JP (1) JP2023524112A (fr)
CA (1) CA3181788A1 (fr)
WO (1) WO2021222569A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213108A1 (fr) * 2021-03-09 2022-09-15 Robert E. Blomquist Procedes de test de pathogenes sans extraction
US20230142838A1 (en) * 2021-11-08 2023-05-11 Summit Biolabs, Inc. Devices and methods for nucleic acid extraction-free sti pathogen testing
WO2023234336A1 (fr) * 2022-05-31 2023-12-07 感染症創薬研究所株式会社 Procédé de prétraitement d'échantillon pour test immunochromatographique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092360A2 (fr) * 2003-04-10 2004-10-28 Chiron Corporation Le coronavirus du syndrome respiratoire aigu grave

Also Published As

Publication number Publication date
WO2021222569A1 (fr) 2021-11-04
EP4143348A1 (fr) 2023-03-08
US20210341480A1 (en) 2021-11-04
EP4143348A4 (fr) 2024-01-17
JP2023524112A (ja) 2023-06-08

Similar Documents

Publication Publication Date Title
US20210341480A1 (en) Viral testing in saliva
Sampson et al. A four-biomarker blood signature discriminates systemic inflammation due to viral infection versus other etiologies
US11884978B2 (en) Pathogen biomarkers and uses therefor
Lloyd et al. Conventional parasitology and DNA-based diagnostic methods for onchocerciasis elimination programmes
Shirazi et al. Testing for COVID-19 in dental offices: mechanism of action, application, and interpretation of laboratory and point-of-care screening tests
Cardona et al. Detection of Toxoplasma DNA in the peripheral blood of HIV-positive patients with neuro-opportunistic infections by a real-time PCR assay
Abdulrahman et al. Comparison of SARS-COV-2 nasal antigen test to nasopharyngeal RT-PCR in mildly symptomatic patients
CN116171198A (zh) 用于快速早期检测感染的宿主rna生物标志物和早期鉴定人的covid-19冠状病毒感染的系统、方法和组合物
Simpson et al. Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques
Randriamahazo et al. Evaluation of antigen-based rapid detection test for the diagnosis of SARS CoV-2 in low-income countries
Santos Bravo et al. Severe acute respiratory syndrome coronavirus 2 normalized viral loads and subgenomic RNA detection as tools for improving clinical decision making and work reincorporation
Fitoussi et al. Performances of the VitaPCR™ SARS‐CoV‐2 Assay during the second wave of the COVID‐19 epidemic in France
Lamikanra et al. A direct comparison of real time PCR on plasma and blood to detect Plasmodium falciparum infection in children
Mannan et al. Detection of SARS-CoV-2 RNA by reverse transcription-polymerase chain reaction (RT-PCR) on self-collected nasal swab compared with professionally collected nasopharyngeal swab
US10078086B2 (en) Use of interleukin-27 as a diagnostic biomarker for bacterial infection in critically ill patients
Kim et al. Diagnostic performance of respirators for collection and detection of SARS-CoV-2
Qamruddin et al. Measles in Larut, Matang and Selama: Analysis and evaluation of clinical case definitions for 2015-2019
Hernandez et al. Rationale and design of the Anal HPV, HIV and Aging (AHHA) study: Protocol for a prospective study of anal HPV infection and HSIL among men who have sex (MSM) or trans women living with and without HIV, ages 50 and older
Huang et al. CRISPR-based assay reveals SARS-CoV-2 RNA dynamic changes and redistribution patterns in non-human primate model
WO2023020638A1 (fr) Procédé pour prédire la gravité d'une maladie infectieuse et biomarqueur à utiliser pour la mise en oeuvre du procédé et le suivi d'une thérapie pour une maladie infectieuse
EP3438281A1 (fr) Biomarqueur du stress
RU2706126C1 (ru) Способ диагностики активности сочетанной инфекции у детей с острыми респираторными инфекциями
Salvagno et al. Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing
Afzal et al. DIAGNOSTIC ACCURACY OF PANBIO COVID-19 RAPID ANTIGEN METHOD FOR SCREENING IN EMERGENCY CASES: Panbio COVID-19 Rapid Antigen Method
Turner et al. SARS-CoV-2 Rapid Antigen Kit Efficacy in Comparison with Quant Studio 12 PCR